Daniel M. Halperin, MD

Background

A board-certified medical oncologist, Daniel M. Halperin, MD, specializes in the treatment of neuroendocrine tumors (NETs). Dr. Halperin is a physician on the gastrointestinal oncology team at Winship Cancer Institute of Emory University.

Dr. Halperin is an associate professor and serves as vice chair for clinical affairs in the Department of Hematology and Medical Oncology at Emory University School of Meecine. As vice chair of clinical affairs, he works with the department chair and other leaders to plan, communicate and execute Winship strategies and organizational goals in the clinical arena, and to support and direct the performance of physician faculty members in the department.

Dr. Halperin received his medical degree from Weill Cornell Medical College in New York City, New York. He completed his internal medicine residency at Brigham and Women's Hospital in Boston, Massachusetts and his medical oncology training at University of Texas MD Anderson Cancer Center in Houston, Texas.

Titles & Roles

• Associate Professor, Department of Hematology and Medical Oncology

  Emory University School of Medicine
• Vice Chair of Clinical Affairs, Department of Hematology and Medical Oncology

  Emory University School of Medicine

Education & Training

Education

• Fellowship, Hematology/Oncology, 2015

  University of Texas M. D. Anderson Cancer Center, Houston, TX
• Residency, Internal Medicine, 2012

  Brigham and Women's Hospital
• Internship, Internal Medicine, 2010

  Brigham and Women's Hospital
• Medical Education, MD, 2009

  Weill Cornell Medical College

Board Certifications

• Medical Oncology

  American Board of Internal Medicine, 2015
• Internal Medicine

  American Board of Internal Medicine, 2013

Professional Memberships

Dr. Halperin serves on the Board of Scientific Advisors of the NET Research Foundation, the Scientific Advisory Committee of the Healing NET Foundation and the Board of Directors and Symposium Committee of the North American Neuroendocrine Tumor Society.

Research

As a clinical investigator, Halperin is dedicated to providing world-class clinical care and developing novel therapies for patients with neuroendocrine tumors (NETs), which are tumors that develop from a diffuse network of neuroendocrine cells that make and release hormones into the bloodstream to control essential bodily functions. He has played a leading role in clinical trials of immunotherapy and radioligands for patients with NETs. He also collaborates with laboratory and population scientists to deepen our understanding of the molecular basis and clinical presentation of neuroendocrine tumors.

Publications

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.